2 research outputs found
BĹ‘rkĂmĂ©lĹ‘ (skin-sparing) mastectomia Ă©s azonnali emlĹ‘rekonstrukciĂł onkolĂłgiai biztonságossága a recidĂvaarány, recidĂvalokalizáciĂł Ă©s a rekonstrukciĂłs technika fĂĽggvĂ©nyĂ©ben | Oncologic safety of skin-sparing mastectomy followed by immediate breast reconstruction: rate and localization of recurrences, and impact of reconstruction techniques
BevezetĂ©s: A bĹ‘rkĂmĂ©lĹ‘ mastectomia Ă©s az azonnali emlĹ‘rekonstrukciĂł onkosebĂ©szeti biztonságossága megkĂ©rdĹ‘jelezhetĹ‘. A rendelkezĂ©sre állĂł evidencia a legtöbb esetben szelektált betegcsoportok rövid távĂş utánkövetĂ©sĂ©n alapul. CĂ©l: A szerzĹ‘k tanulmányukban egy nem szelektált betegcsoport 10 Ă©ves onkolĂłgiai utánkövetĂ©sĂ©nek adatait elemzik. MĂłdszerek: 253, bĹ‘rkĂmĂ©lĹ‘ mastectomiával Ă©s azonnali emlĹ‘rekonstrukciĂłval kezelt beteg utánkövetĂ©si adatainak retrospektĂv elemezĂ©sĂ©t vĂ©geztĂ©k. Minden, emlĹ‘carcinomával diagnosztizált betegnek felajánlották az azonnali emlĹ‘rekonstrukciĂłt a tumor stádiumátĂłl fĂĽggetlenĂĽl („all-comers” mĂłdszer). EredmĂ©nyek: Az „all-comers” mĂłdszer eredmĂ©nyekĂ©pp a betegek viszonylag nagy hányada elĹ‘rehaladott emlĹ‘rákkal kerĂĽlt műtĂ©tre. 119 hĂłnapos átlagos utánkövetĂ©si idĹ‘ alatt a lokoregionális recidĂva aránya 8,2%, a distalis kiĂşjulás 10,6% volt. A betegek emlĹ‘rák-specifikus tĂşlĂ©lĂ©se 90,9% volt. AutolĂłg szövettel vĂ©gzett emlĹ‘rekonstrukciĂłt gyakrabban alkalmaztak magasabb tumorstádium esetĂ©n, ezĂ©rt a recidĂvák gyakorisága magasabb volt, mint implantátummal vĂ©gzett emlĹ‘rekonstrukciĂłk után. KövetkeztetĂ©s: A hosszĂş távĂş utánkövetĂ©sen alapulĂł eredmĂ©nyek szerint a bĹ‘rkĂmĂ©lĹ‘ mastectomia Ă©s az azonnali emlĹ‘rekonstrukciĂł onkolĂłgiailag megbĂzhatĂł kezelĂ©si mĂłdszer. Mivel az „all-comers” mĂłdszer alkalmazása onkolĂłgiailag biztonságosnak bizonyult, ezĂ©rt azonnali emlĹ‘rekonstrukciĂł a tumorstádiumtĂłl fĂĽggetlenĂĽl felajánlhatĂł. Orv. Hetil., 2013, 154, 163–171.
|
Introduction: Oncological safety of skin-sparing mastectomy followed by immediate breast reconstruction is widely debated. Current evidence is relatively poor since it is based mostly on short-term follow-up data of highly selected patient populations. Aim: Recurrence rates of a large cohort of non-selected patients, i. e. “all-comers” were analyzed during a 10-year follow up. Methods: Patient records and follow-up data of 253 consecutive cases treated with of skin-sparing mastectomy and immediate breast reconstruction between 1995 and 2000 were studied. During this time period “all-comers” policy was applied, which meant that all patients treated with mastectomy were offered immediate breast reconstruction regardless of tumour stage. Results: “All-comers” approach resulted in a large proportion of patients with more advanced disease. During the 112 months mean follow-up 8.2% locoregional, 2.9% local, 10.6% distal and 18.8% overall recurrence rates were detected. Breast cancer specific survival rate was 90.9%. Autologous breast reconstruction was applied more frequently in patients with higher tumour stage; therefore recurrence rate was higher compared to patients undergoing implant-based reconstruction. Conclusion: Based on these long-term follow-up data skin-sparing mastectomy combined with immediate breast reconstruction is an oncologically safe treatment option. Therefore, application of “all-comers” policy for breast cancer patients treated with skin-sparing mastectomy followed by immediate breast reconstruction is feasible. Orv. Hetil., 2013, 154, 163–171
Terápiás emlĹ‘plasztika intraoperatĂv, közvetlen posztoperatĂv Ă©s hosszĂş távĂş onkosebĂ©szeti biztonsága | Intraoperative, postoperative and long-term oncosurgical safety of therapeutic mammaplasty
BevezetĂ©s: Az onkoplasztikai emlĹ‘sebĂ©szeti mĂłdszerek alkalmazásával a hagyományosan mastectomiával kezelt (pre)malignus emlĹ‘elváltozások is eltávolĂthatĂłk emlĹ‘megtartĂł műtĂ©ttel (terápiás emlĹ‘plasztika). A mĂłdszer onkosebĂ©szeti megbĂzhatĂłságára ugyanakkor nincsenek megfelelĹ‘ adatok. CĂ©lkitűzĂ©s: A szerzĹ‘k cĂ©lul tűztĂ©k ki a terápiás emlĹ‘plasztika onkosebĂ©szeti biztonságának meghatározását. MĂłdszer: 99 beteget kezeltek terápiás emlĹ‘plasztikával Ă©s az eredmĂ©nyeket folyamatosan vezetett emlĹ‘sebĂ©szeti adatbázis alapján elemeztĂ©k. Az intraoperatĂv, a közvetlen posztoperatĂv, illetve a hosszĂş távĂş onkolĂłgiai biztonságot vizsgálták. EredmĂ©nyek: A betegek 14,1%-ában voltak a reszekciĂłs szĂ©lek inkomplettek, amelyek korreláltak a tumormĂ©rettel (p = 0,023) Ă©s a multifokális elváltozásokkal (p = 0,012). A terápiás emlĹ‘plasztika Ă©s a kemoterápia megkezdĂ©se közötti idĹ‘intervallum hasonlĂł volt a mastectomiával, egyszerű szĂ©les excisiĂłval, vagy mastectomiával Ă©s azonnali rekonstrukciĂłval kezelt betegekĂ©hez (átlagosan 29–31 nap; p<0,05). 27 hĂłnapos (1–88) átlagos utánkövetĂ©si idĹ‘ alatt a recidĂva aránya 6,1%, ebbĹ‘l a lokális recidĂva aránya 2% volt. KövetkeztetĂ©sek: Mivel az irodalmi adatok is hasonlĂłan rövid utánkövetĂ©si idĹ‘szakon Ă©s alacsony betegszámon alapulnak, kulcsfontosságĂş, hogy minden emlĹ‘centrum, ahol terápiás emlĹ‘plasztikát vĂ©geznek, folyamatosan vezetett adatbázist kĂ©szĂtsen a hosszĂş távĂş recidĂvaarány meghatározása cĂ©ljábĂłl. Orv. Hetil., 2013, 154, 1291–1296.
|
Introduction: (Pre)malignant lesion in the breast requiring mastectomy conventionally may be treated with breast conservation by using oncoplastic breast surgical techniques, which is called therapeutic mammaplasty. However, no reliable data has been published so far as regards the oncological safety of this method. Aim: The aim of the authors was to analyse the oncological safety of therapeutic mammaplasty in a series of patients. Method: 99 patients were treated with therapeutic mammaplasty and data were collected in a breast surgical database prospectively. Results were analysed with respect to intraoperative, postoperative and long-term oncological safety. Results: Incomplete resection rate was 14.1%, which correlated with tumour size (p = 0.023), and multifocality (p = 0.012). Time between surgery (therapeutic mammaplasty) and chemotherapy was similar to time between conventional breast surgeries (wide excision, mastectomy, mastectomy with immediate reconstruction) and chemotherapy (mean 29–31 days; p<0.05). Overall recurrence rate was 6.1%, locoregional recurrence rate was 2% during 27 month (1–88) mean follow-up. Conclusions: Since literature data are based on relatively short follow-up and low patient number, it is highly important that all data on therapeutic mammaplasty is collected in a prospectively maintained breast surgical database in order to determine true recurrence after long-follow-up. Orv. Hetil., 2013, 154, 1291–1296